Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0033774 (pruritus)
 14,546 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

The development of the syndrome of chronic intrahepatic cholestasis in five young, black men who had systemic granulomatous disease and clinical features consistent with those of sarcoidosis is described. Clinical and biochemical aspects, similar to those of primary biliary cirrhosis, included pruritus, jaundice, hepatomegaly and striking elevations of serum levels of alkaline phosphatase and cholesterol. (One patient had skin xanthomas.) Mitochondrial antibodies were not found; and survival of the patients (7 to 18 years) exceeded the usual survival of patients with primary biliary cirrhosis. The histologic abnormalities included noncaseating granulomas, chronic intrahepatic cholestasis, increased copper in hepatocytes, progressive diminution in number of interiobular bile ducts, periportal fibrosis and the eventual development of a micronodular "biliary" cirrhosis. The histologic evolution of the disease suggests a slow, progressive destruction of the bile ducts by granulomas. Although the end stage of this syndrome resembles primary biliary cirrhosis, the characteristic nonsuppurative, destructive cholangitis of primary biliary cirrhosis was not present.
Am J Med 1975 Sep
PMID:Chronic intrahepatic cholestasis of sarcoidosis. 116 46

6 cases of acrodermatitis papulosa eruptiva infantum (acrodermatitis papulosa infantilis or Gianotti-Crostisyndrome: G.C.S.) were observed and the clinical features of this disease are discussed. 1. An erythemato-papular dermatitis mainly of the face, legs, arms, buttocks, not itching, without re-occurrence lasting on the average 20--25 days. 2. An distinct enlargement of the lymph nodes, especially of the inguinal and axillary areas (reactive reticulo-histocytic lymphadenitis). 3. Acute hepatitis, mostly without icterus. 4. Presence of HB Ag-Australia Antigen in the serum of patients a few days after the onset of the disease. Doubts concerning the entity of G.C.S. are getting irrelevant considering the distinct characteristics. The viral genesis already suggested by Gianotti and Crosti of the picture of the disease seems to be true: in all cases Australian antigens are positive. The infectiousness, but the small danger of infection, even if the disease dates back a few months, should not be underestimated. When diagnosing G.C.S. among others the akrolocalized papular-vesicular syndrome described by Crosti and Gianotti should be considered. In 2 patients we could find by electron microscopic studies microtubular aggregates having a diameter of 200 A. These aggregates were situated in the cytoplasm of endothelial cells of smaller vessels in the upper part of the corium.
Hautarzt 1975 Sep
PMID:[Entity of the Gianotti-Crosti's syndrome and its relation to hepatitis B infection]. 118 90

Two new methods are described for the quantitative measurement of itch: the principle is to measure scratch which is the major objective correlate of itch. The first method is to record whole body movement at night by a vibration transducer on a bed leg; this gives qualitative and quantitative information. The second method is to measure limb movement with movement-sensitive meters; this give only quantitative data but is quicker and more easily carried out. The subjective sensation of itch was found to correlate well with nocturnal scratch, confirming the basic assumption of the method. Itching as measured by scratch occurs throughout the night and increased severity of itch is accompanied by an increase in the number of bouts of itch and not in their duration. Nocturnal restlessness is associated with an increase in leg movement and so can be dissociated from itch-provoked scratch, which is mostly done by the hands. The response of pruritus to treatment was demonstrated by both methods.
Br J Dermatol 1975 Sep
PMID:A new method for the measurement of itch and the response to treatment. 119 38

In the light of current epidemiological data, demonstrating a high prevalence of genitoanal papilloma virus infection (GPVI) existing merely in a subclinical or latent form, ambiguity has emanated on the level of ambition that should be considered optimal for the management of GPVI in the male. This review addresses a pragmatic approach to the problem, with an emphasis on diagnosing and treating overt condylomas causing psychosexual disturbance because of the growth of disfiguring but medically rather innocent condylomas, and of flat acetowhite lesions that cause symptoms such as itching, burning, and dyspareunia. The evaluation of children afflicted with genitoanal warts is elucidated. The significance of intraepithelial neoplastic transformation associated with high-risk human papillomavirus (HPV) types such as HPV 16 is discussed, with reference to immunocompetent and immunosuppressed men. Although unequivocal histopathological signs of HPV influence often are absent, conventional light microscopy is usually adequate for differential diagnostic evaluation in clinical routine. In situ hybridization for the detection of HPV DNA may improve histopathologic accuracy.
Semin Dermatol 1992 Sep
PMID:Clinical relevance and evaluation of genitoanal papilloma virus infection in the male. 132 56

The twofold purpose of this study was to assess the prevalence of latex sensitivity in a large group of operating room nurses and to evaluate the relationship between questionnaire responses and skin tests. Of the total target population of 268 operating room nurses, 248 (93%) answered the questionnaire and 197 had skin prick tests to latex (1/10 wt/vol solution). Symptoms associated with glove wearing were acknowledged by 41.1% of nurses. Skin tests to latex were positive in 21 nurses (10.7%), 4.4 times more often in atopic nurses. Among nurses complaining of local symptoms, only 18.6% had positive skin tests. Itching of the hands during glove wearing correlated poorly with latex sensitivity, but correlation with local urticaria was better. Atopic nurses complaining of urticaria had latex allergy in 70% of cases. Thus latex allergy is common in nurses, especially atopic nurses. A questionnaire is unreliable in predicting latex sensitivity and must be supported by latex skin test. More data will be needed to assess the risk of anaphylactic perioperative reactions in operating room nurses.
J Allergy Clin Immunol 1992 Sep
PMID:Prevalence of latex allergy in operating room nurses. 152 11

Forty-three patients recruited from general practice with symptom-producing chronic venous insufficiency in the lower limbs participated in a randomized double-blind clinical trial with Venoruton (300 mg x 3) or a placebo for 28 days. Twenty-eight patients were treated with Venoruton and 19 with a placebo. None of the patients received other forms of treatment for chronic venous insufficiency. No differences were observed between the two groups as regards changes in symptoms (swelling, pain, heaviness, restlessness, itching and cramps) the subjective assessment of the discomfort in the extremities or the circumference of the limbs. Venoruton does not appear to have any effect on chronic venous insufficiency in the lower limbs.
Ugeskr Laeger 1992 Sep 14
PMID:[Effect of 0-(beta-hydroxyethyl)-rutoside (Venoruton) on symptomatic venous insufficiency in the lower limbs]. 141 83

Research on itch has been hampered by difficulties in measuring the itch sensation. A microcomputer-based system, where the patients themselves record their symptoms on portable data loggers can be used for quantitative measurements of clinical itch and for the detection of antipruritic effects of drugs. By using this system we have found that itch in atopic dermatitis is not inhibited by antihistamines but by cyclosporin A, a drug inhibiting cytokine production. Thus histamine is not a major pruritogen in atopic dermatitis. A hypothesis is proposed that cytokines are involved in itch in atopic dermatitis.
J Dermatol Sci 1992 Sep
PMID:Some methods for evaluating clinical itch and their application for studying pathophysiological mechanisms. 141 79

The efficacy and safety of a new non-sedating antihistamine, loratadine (Clarityn, CAS 79794-75-5) 10 mg q.d., was compared to the classical antihistamine, hydroxyzine 25 mg t.i.d. and placebo in a 4-week (optional 12 week) randomized, double-blind, multi-center study in 203 patients with chronic idiopathic urticaria. Efficacy evaluations included weekly physician and patient assessments of pruritus, overall disease condition, and therapeutic response to treatment. Loratadine and hydroxyzine were significantly more effective than placebo and clinically comparable to each other as measured by all efficacy evaluations at each visit. Loratadine was safe and well tolerated with sedation and dry mouth similar to placebo and significantly less than hydroxyzine.
Arzneimittelforschung 1992 Sep
PMID:Relative efficacy and safety of loratadine, hydroxyzine, and placebo in chronic idiopathic urticaria. 144 78

A total of 725 patients with mycosis of the skin folds, large areas of the body or feet were entered into this double-blind, dose-finding study. Treatment with 0.125, 0.25 or 0.5% amorolfine cream was randomly allocated to patients. The cream was applied once daily for 4 weeks on average. At screening, in 527 patients evaluated for efficacy, a total of 533 pathogens were isolated: T. rubrum (322), T. mentagrophytes (84), E. floccosum (45), M. canis (42), other dermatophytes (14), C. albicans (24) and other yeasts (2). One week after the end of treatment, the culture was negative in 80.5, 81.3 and 84.8% of patients treated with 0.125, 0.25 or 0.5% amorolfine cream, respectively. The differences were not statistically significant. Forty-four out of 714 patients evaluated for safety had local adverse events: 14 (5.8%), 13 (5.5%) and 17 (7.1%) in the amorolfine cream 0.125, 0.25 and 0.5% groups, respectively. Due to local adverse events, six patients (2.5%) in the 0.125% group, six patients (2.6%) in the 0.25% group and seven patients (2.9%) in the 0.5% group discontinued the trial treatment. The most common adverse events were burning, itching, erythema and scaling. No systemic adverse events were reported.
Clin Exp Dermatol 1992 Sep
PMID:Dose-finding study of amorolfine cream (0.125%, 0.25% and 0.5%) in the treatment of dermatomycoses. 145 66

A total of 232 patients with mycoses of skin folds, body, or feet were entered into a double-blind, parallel group-study. Therapy with 0.125, 0.25, 0.5% amorolfine cream or 1% bifonazole cream was randomly allocated to patients. The cream was applied once daily for 4 weeks on average. At screening, in 208 patients evaluated for efficacy, a total of 225 fungi were isolated: T. rubrum (77), T. mentagrophytes (65), other dermatophytes (15), C. albicans (34), other yeasts (26) and moulds (8). One to three weeks after ending therapy, the percentage of patients with negative cultures were as follows: 87.3, 91.7, 90.7 and 92.2% in the amorolfine cream 0.125%, 0.25%, 0.5% and bifonazole cream 1% groups respectively. The differences were not statistically significant. Six out of 223 patients evaluated for safety had local adverse events: one (1.7%), two (3.6%) and three (5.4%) in the amorolfine cream 0.125%, 0.25% and bifonazole cream 1% groups respectively. The most common local adverse events were burning and increased itching, erythema or weeping. A once-daily application of amorolfine cream can be recommended for the treatment of dermatomycoses on the basis of the results from this study. However, a further and similar study with a larger number of patients was required to select the concentration of amorolfine cream for therapeutic use.
Clin Exp Dermatol 1992 Sep
PMID:Double-blind comparison of amorolfine and bifonazole in the treatment of dermatomycoses. 145 67


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>